Greenwich LifeSciences Inc. (GLSI)
Market Closed
15 Dec, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
10. 37
-0.37
-3.4%
After Hours
$
+1.82 +17.61% 12. 19
115.59M Market Cap
- P/E Ratio
0% Div Yield
3,860,386 Volume
-0.68 Eps
$ 10.73
Previous Close Day Range
10.11 14.19
Year Range
7.78 14.47
Want to track GLSI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100
Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b study indicated that patients, given GLSI-100 for HER2/neu positive breast cancer, were able to achieve a 100% recurrence free rate. The global breast cancer market size is expected to be worth $49.2 billion by 2032.
Seekingalpha | 1 year ago
2025 © Marketlog. All Rights Reserved.
